In:
International Journal of Cancer, Wiley, Vol. 145, No. 10 ( 2019-11-15), p. 2712-2719
Abstract:
What's new? While most HPV infections clear up on their own, persistent infections can lead to cancer. No antiviral drugs are currently available to fight HPV infection. In this paper, the authors tested a proprietary biologic antiviral they developed, called REBACIN®. The drug successfully eliminated HPV infection in 60% of treated patients, while in the control group only 20% of infections cleared on their own. All patients began the trial with high‐risk HPV infection lasting one year or more. The authors also found that REBACIN® inhibited mRNA transcription of HPV oncogenes E6/E7 and reduced E6/E7‐stimulated tumor growth in mice.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8